JP7705475B2 - Ｋｈｋ阻害剤 - Google Patents

Ｋｈｋ阻害剤 Download PDF

Info

Publication number
JP7705475B2
JP7705475B2 JP2023560087A JP2023560087A JP7705475B2 JP 7705475 B2 JP7705475 B2 JP 7705475B2 JP 2023560087 A JP2023560087 A JP 2023560087A JP 2023560087 A JP2023560087 A JP 2023560087A JP 7705475 B2 JP7705475 B2 JP 7705475B2
Authority
JP
Japan
Prior art keywords
inhibitors
dihydro
cyclopenta
methylazetidin
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023560087A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024512646A (ja
Inventor
ジェイムズ エル． バックマン，
ダニエル エイチ． ビュン，
クリストファー ティー． クラーク，
ペーテル ヤンサ，
ジョシュア エー． カプラン，
ザッカリー エー． カスン，
ジェニファー アール． ロ，
メーガン イー． ニュービッグ，
ナサニエル エイチ． スタンレー，
カーク エル． スティーブンズ，
Original Assignee
ギリアード サイエンシーズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ギリアード サイエンシーズ， インコーポレイテッド filed Critical ギリアード サイエンシーズ， インコーポレイテッド
Publication of JP2024512646A publication Critical patent/JP2024512646A/ja
Priority to JP2024211090A priority Critical patent/JP7778900B2/ja
Application granted granted Critical
Publication of JP7705475B2 publication Critical patent/JP7705475B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023560087A 2021-03-29 2022-03-25 Ｋｈｋ阻害剤 Active JP7705475B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024211090A JP7778900B2 (ja) 2021-03-29 2024-12-04 Ｋｈｋ阻害剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163167331P 2021-03-29 2021-03-29
US63/167,331 2021-03-29
PCT/US2022/021912 WO2022212194A1 (en) 2021-03-29 2022-03-25 Khk inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024211090A Division JP7778900B2 (ja) 2021-03-29 2024-12-04 Ｋｈｋ阻害剤

Publications (2)

Publication Number Publication Date
JP2024512646A JP2024512646A (ja) 2024-03-19
JP7705475B2 true JP7705475B2 (ja) 2025-07-09

Family

ID=81388962

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023560087A Active JP7705475B2 (ja) 2021-03-29 2022-03-25 Ｋｈｋ阻害剤
JP2024211090A Active JP7778900B2 (ja) 2021-03-29 2024-12-04 Ｋｈｋ阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024211090A Active JP7778900B2 (ja) 2021-03-29 2024-12-04 Ｋｈｋ阻害剤

Country Status (12)

Country Link
US (2) US12410160B2 (https=)
EP (2) EP4681774A3 (https=)
JP (2) JP7705475B2 (https=)
KR (1) KR20230158542A (https=)
CN (1) CN117120429A (https=)
AR (1) AR125238A1 (https=)
AU (2) AU2022252182B2 (https=)
CA (1) CA3214961A1 (https=)
ES (1) ES3061522T3 (https=)
PL (1) PL4313967T3 (https=)
TW (2) TW202448875A (https=)
WO (1) WO2022212194A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230098069A (ko) * 2021-12-24 2023-07-03 주식회사 엘지화학 (s)-2-(2-메틸아제티딘-1-일)피리미딘 유도체 및 이를 포함하는 약제학적 조성물
CN119923397A (zh) * 2022-10-24 2025-05-02 柳韩洋行 用于制备二甲基-2,3-二氢-1h-茚衍生物的改进方法
WO2024125482A1 (zh) * 2022-12-13 2024-06-20 华领医药技术（上海）有限公司 作为己酮糖激酶抑制剂的化合物、其用途以及包含其的组合物
WO2025184056A1 (en) * 2024-02-26 2025-09-04 Miralogx Llc Synthetic cannabinoid analogs, pharmaceutical compositions and methods of treating anxiety and other disorders
WO2025250674A1 (en) * 2024-05-30 2025-12-04 Miralogx Llc Synthetic cannabinoid analogs, pharmaceutical compositions and methods of treating neurological disorders and other conditions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020156445A1 (zh) 2019-01-29 2020-08-06 山东轩竹医药科技有限公司 己酮糖激酶抑制剂及其用途
WO2020257171A1 (en) 2019-06-17 2020-12-24 Eli Lilly And Company Disubstituted pyrazole compounds as ketohexokinase inhibitors
WO2021129737A1 (zh) 2019-12-24 2021-07-01 南京明德新药研发有限公司 具有khk抑制作用的化合物
WO2022135390A1 (zh) 2020-12-25 2022-06-30 四川海思科制药有限公司 己酮糖激酶抑制剂及其用途

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041443A (en) * 1989-02-21 1991-08-20 Dainippon Pharmaceutical Co., Ltd. Medicament for treating cerebral insufficiency diseases, novel 2-(1-piperazinyl)-4-phenylcycloalkanopyrimidine derivatives, and process for the production thereof
US5137890A (en) 1990-02-14 1992-08-11 Ortho Pharmaceutical Corporation 4-phenyl tetrahydropyrido(4,3-d)pyrimidines
GB0100620D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical cokpounds V
DE602004014347D1 (de) * 2003-03-12 2008-07-24 Millennium Pharm Inc Chinazolin-derivate als tgf-beta-inhibitoren
JP2007510642A (ja) * 2003-11-03 2007-04-26 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 中枢神経系障害の治療のための新規ノルエピネフリン再取込み阻害薬
WO2007019083A1 (en) 2005-08-04 2007-02-15 Janssen Pharmaceutica N.V. Pyrimidine compounds as serotonin receptor modulators
US7851468B2 (en) * 2006-05-15 2010-12-14 Cephalon, Inc. Substituted pyrazolo[3,4-d]pyrimidines
WO2009045174A1 (en) * 2007-10-05 2009-04-09 S*Bio Pte Ltd 2-morpholinylpurines as inhibitors of pi3k
WO2010053825A1 (en) 2008-10-29 2010-05-14 Janssen Pharmaceutica Nv 2-aminopyrimidine compounds as serotonin receptor modulators
AU2009314544C1 (en) * 2008-11-11 2015-11-12 Xcovery Holding Company Llc PI3K/mTOR kinase inhibitors
TWI598347B (zh) 2009-07-13 2017-09-11 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
US8822447B2 (en) 2010-04-22 2014-09-02 Janssen Pharmaceutica Nv Indazole compounds useful as ketohexokinase inhibitors
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
RS57157B1 (sr) 2011-11-11 2018-07-31 Gilead Apollo Llc Acc inhibitori i njihove primene
UY34573A (es) 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
US9499561B2 (en) * 2012-04-10 2016-11-22 Shanghai Yingli Pharmaceutical Co., Ltd. Fused pyrimidine compound, and preparation method, intermediate, composition, and uses thereof
MX2017003933A (es) 2014-09-24 2017-06-30 Gilead Sciences Inc Metodos de tratamiento de la enfermedad hepatica.
CN112225699B (zh) 2014-12-23 2023-11-14 吉利德科学公司 制备ask1抑制剂的方法
MA41252A (fr) 2014-12-23 2017-10-31 Gilead Sciences Inc Formes solides d'un inhibiteur d'ask 1
EA201791258A1 (ru) 2015-01-09 2017-12-29 Джилид Аполло, Ллс Комбинированная терапия с применением ингибитора ацетил-коа-карбоксилазы (acc) для лечения неалкогольной жировой болезни печени
WO2017027611A2 (en) * 2015-08-10 2017-02-16 The Arizona Board Of Regents On Behalf Of The University Of Arizona Biomarkers of methylglyoxal and related methods thereof
SI3397631T1 (sl) 2015-12-29 2022-01-31 Pfizer Inc. Substituirani 3-azabiciklo(3.1.0)heksani kot zaviralci ketoheksokinaze
SG11201807077RA (en) 2016-03-02 2018-09-27 Gilead Apollo Llc Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof
CN110382503B (zh) 2017-03-03 2022-07-19 吉利德科学公司 制备acc抑制剂及其固体形式的方法
CA3056890A1 (en) 2017-03-17 2018-09-20 Regents Of The University Of Colorado, A Body Corporate Indazole inhibitors of fructokinase (khk) and methods of use in treating khk-mediated disorders or diseases
JP2020512342A (ja) 2017-03-28 2020-04-23 ギリアード サイエンシーズ， インコーポレイテッド 肝疾患を処置する方法
SI4122464T1 (sl) 2017-03-28 2024-07-31 Gilead Sciences, Inc. Terapevtske kombinacije za zdravljenje bolezni jeter
JP2020516627A (ja) 2017-04-12 2020-06-11 ギリアード サイエンシーズ， インコーポレイテッド 肝疾患を処置する方法
US10980810B2 (en) 2017-10-06 2021-04-20 Gilead Sciences, Inc. Combination therapy comprising an ACC inhibitor
US12161621B2 (en) 2018-07-16 2024-12-10 The Regents Of The University Of Colorado Methods for fructokinase mediation of alcohol craving and alcohol induced liver disease
TWI714231B (zh) 2018-09-04 2020-12-21 美商美國禮來大藥廠 2,6-二胺基吡啶化合物
KR102558308B1 (ko) 2018-09-27 2023-07-24 주식회사 엘지화학 3-아자바이사이클로[3,1,1]헵탄 유도체 및 이를 포함하는 약제학적 조성물
JP2022519906A (ja) 2019-02-19 2022-03-25 ギリアード サイエンシーズ， インコーポレイテッド Ｆｘｒアゴニストの固体形態
WO2020185685A1 (en) 2019-03-08 2020-09-17 The Regents Of The University Of California Compositions and methods for treating acne
WO2020215022A1 (en) 2019-04-17 2020-10-22 Colorado Research Partners, Llc Novel compounds and methods of use treating fructose-related disorders or diseases
CN111978296A (zh) 2019-05-22 2020-11-24 山东轩竹医药科技有限公司 己酮糖激酶抑制剂及其用途
CN114846008B (zh) 2019-12-25 2024-05-28 杭州中美华东制药有限公司 具有果糖激酶(khk)抑制作用的嘧啶类化合物
WO2021162943A1 (en) 2020-02-13 2021-08-19 Eli Lilly And Company 2-[2-methylazetidin-1-yl]-4-phenyl-6-(trifluoromethyl)-pyrimidine compounds
CN111423420A (zh) 2020-04-30 2020-07-17 广州博济医药生物技术股份有限公司 作为己酮糖激酶抑制剂的并环化合物
CN114181198B (zh) 2020-09-15 2025-07-15 山东轩竹医药科技有限公司 嘧啶衍生物类己酮糖激酶抑制剂及其用途
CN114805312A (zh) 2021-01-29 2022-07-29 上海拓界生物医药科技有限公司 一种己酮糖激酶抑制剂及其制备方法
CN114989143A (zh) 2021-03-02 2022-09-02 山东轩竹医药科技有限公司 并环类己酮糖激酶抑制剂及其用途
WO2022211595A1 (ko) 2021-04-01 2022-10-06 주식회사 엘지화학 옥사디아졸 화합물 및 이를 포함하는 약제학적 조성물

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020156445A1 (zh) 2019-01-29 2020-08-06 山东轩竹医药科技有限公司 己酮糖激酶抑制剂及其用途
WO2020257171A1 (en) 2019-06-17 2020-12-24 Eli Lilly And Company Disubstituted pyrazole compounds as ketohexokinase inhibitors
WO2021129737A1 (zh) 2019-12-24 2021-07-01 南京明德新药研发有限公司 具有khk抑制作用的化合物
WO2022135390A1 (zh) 2020-12-25 2022-06-30 四川海思科制药有限公司 己酮糖激酶抑制剂及其用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Kentaro Futatsugi et al.，Discovery of PF-06835919: A Potent Inhibitor of Ketohexokinase (KHK) for the Treatment of Metabolic Disorders Driven by the Overconsumption of Fructose，J. Med. Chem.，2020年，63，13546-13560，DOI: 10.1021/acs.jmedchem.0c00944

Also Published As

Publication number Publication date
TW202246253A (zh) 2022-12-01
AU2022252182A1 (en) 2023-09-28
US12410160B2 (en) 2025-09-09
EP4681774A2 (en) 2026-01-21
US20260092053A1 (en) 2026-04-02
AU2022252182B2 (en) 2025-02-20
EP4313967B1 (en) 2025-11-12
AR125238A1 (es) 2023-06-28
TW202448875A (zh) 2024-12-16
ES3061522T3 (en) 2026-04-06
EP4681774A3 (en) 2026-03-25
KR20230158542A (ko) 2023-11-20
EP4313967A1 (en) 2024-02-07
JP7778900B2 (ja) 2025-12-02
US20230079863A1 (en) 2023-03-16
JP2024512646A (ja) 2024-03-19
PL4313967T3 (pl) 2026-04-20
TWI855308B (zh) 2024-09-11
WO2022212194A1 (en) 2022-10-06
CN117120429A (zh) 2023-11-24
CA3214961A1 (en) 2022-10-06
EP4313967C0 (en) 2025-11-12
JP2025032196A (ja) 2025-03-11
AU2025203602A1 (en) 2025-06-05

Similar Documents

Publication Publication Date Title
JP7705475B2 (ja) Ｋｈｋ阻害剤
CN106103416B (zh) 作为trpm8拮抗剂的氮杂螺衍生物
US10112950B2 (en) Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
EP2968316B1 (en) 2-hydroxy-1-{4-[(4-phenylphenyl)carbonyl]piperazin-1-yl}ethan-1-one derivatives and related compounds as fatty acid synthase (fasn) inhibitors for the treatment of cancer
US20110224197A1 (en) Pyrimidines and pyridines useful as inhibitors of protein kinases
CA3075727A1 (en) Pyridazinones and methods of use thereof
JP7055528B1 (ja) プロテアーゼ阻害剤としてのケトアミド誘導体
NZ528406A (en) Pyridazinone aldose reductase inhibitors
US20240109900A1 (en) Azabicyclic shp2 inhibitors
JP2021521142A (ja) Ｃｒｈｒ２拮抗薬としての縮合環状尿素誘導体
JP2023552469A (ja) アルデヒドデヒドロゲナーゼ阻害剤及びその治療的使用
TW202229243A (zh) 作為新穎二醯基甘油酯o-醯基轉移酶2抑制劑之苯并咪唑酮衍生物的製備
HK40103163A (zh) Khk抑制剂
HK40034427A (en) Novel triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same
HK40043109A (en) Fused cyclic urea derivatives as crhr2 antagonist
HK40043109B (en) Fused cyclic urea derivatives as crhr2 antagonist
NZ752963A (en) Pyrazolopyrimidine compounds and methods of use thereof
HK1220409B (en) 2-hydroxy-1-{4-[(4-phenylphenyl)carbonyl]piperazin-1-yl}ethan-1-one derivatives and related compounds as fatty acid synthase (fasn) inhibitors for the treatment of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230928

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230928

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240904

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241204

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250421

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250624

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250627

R150 Certificate of patent or registration of utility model

Ref document number: 7705475

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150